Wedbush Begins Coverage on Vor Biopharma (NASDAQ:VOR)

Wedbush started coverage on shares of Vor Biopharma (NASDAQ:VOR) in a research report issued to clients and investors on Tuesday, November 25th, Marketbeat Ratings reports. The brokerage set a “neutral” rating on the stock. Wedbush also issued estimates for Vor Biopharma’s Q4 2025 earnings at ($1.11) EPS, Q1 2026 earnings at ($1.25) EPS, Q2 2026 earnings at ($1.43) EPS, Q3 2026 earnings at ($0.93) EPS, Q4 2026 earnings at ($1.08) EPS, FY2026 earnings at ($4.52) EPS, FY2027 earnings at ($9.16) EPS, FY2028 earnings at ($5.74) EPS and FY2029 earnings at ($4.43) EPS.

Several other research firms have also recently issued reports on VOR. Zacks Research raised Vor Biopharma from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Baird R W upgraded Vor Biopharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 15th. Stifel Nicolaus upgraded Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price objective on the stock in a research report on Wednesday, September 24th. HC Wainwright decreased their target price on Vor Biopharma from $55.00 to $32.00 and set a “buy” rating for the company in a report on Friday, November 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $73.17.

Vor Biopharma Trading Down 2.0%

Shares of NASDAQ VOR traded down $0.15 during mid-day trading on Tuesday, hitting $7.53. The stock had a trading volume of 422,468 shares, compared to its average volume of 449,841. The business’s 50 day moving average price is $22.93. Vor Biopharma has a 1 year low of $2.62 and a 1 year high of $65.80. The stock has a market capitalization of $78.39 million, a price-to-earnings ratio of -0.02 and a beta of 2.08.

Vor Biopharma (NASDAQ:VOR) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($3.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.06) by ($0.27).

Insider Buying and Selling

In other news, major shareholder Reprogrammed Interchange Llc sold 447,278 shares of the firm’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $1.54, for a total value of $688,808.12. Following the completion of the transaction, the insider owned 32,781,209 shares in the company, valued at $50,483,061.86. This trade represents a 1.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ra Capital Management, L.P. sold 260,859 shares of Vor Biopharma stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $29.39, for a total value of $7,666,646.01. Following the sale, the director owned 15,104 shares in the company, valued at $443,906.56. This represents a 94.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,327,243 shares of company stock worth $57,827,859 in the last quarter. Company insiders own 0.45% of the company’s stock.

Institutional Trading of Vor Biopharma

A number of hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. grew its position in shares of Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after buying an additional 58,247 shares during the period. XTX Topco Ltd purchased a new position in Vor Biopharma during the 2nd quarter valued at about $66,000. OMERS ADMINISTRATION Corp bought a new stake in Vor Biopharma during the first quarter worth about $100,000. Jane Street Group LLC purchased a new stake in Vor Biopharma in the first quarter worth about $140,000. Finally, Squarepoint Ops LLC purchased a new stake in Vor Biopharma in the third quarter worth about $230,000. Institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.